Weill Cornell’s Dr. Cerchietti Receives Doris Duke Clinical Scientist Award for Study of B-Cell Lymphoma

Dr. Leandro Cerchietti

Dr. Leandro Cerchietti has received a Doris Duke Clinical Scientist Development Award (one of only 12 such awards given yearly by the Doris Duke Foundation). Funding is $150,000 per year spanning 3 years.

Dr. Cerchietti’s project centers on the role of metabolism in determining the clinical behavior of tumors, using metabolomic profiling for the study of B-cell lymphoma.

“Metabolism” is a term that refers to all the biochemical processes of an organ, tumor, or cell, that sustain life. These processes allow cells to grow, reproduce, maintain their structures and respond to environmental changes. Dr. Cerchietti’s study will reveal how — and what — the lymphoma “eats” to survive. It will also explore how these pathways can be “manipulated” in order to “starve them to death.” The goals is to ultimately launch the development of a new class of specific (and non-toxic drugs), and treatments, that could benefit patients with lymphomas.

“We will harness the power of metabolomic profiling to detect certain biological processes in patients; to ascertain whether drugs are hitting their targets in vivo; and to predict clinical outcomes in patients. I think this work has the potential to make important scientific and translational contributions to the diagnosis and treatment of B-cell lymphomas,” says Dr. Cerchietti.

 

Weill Cornell’s Dr. John Leonard Elected Chair of Lymphoma Research Foundation Scientific Advisory Board

 

John Leonard, MD

The Lymphoma Research Foundation (LRF) has announced the election of John Leonard, MD, as the chairman of its Scientific Advisory Board.

Dr. Leonard is the associate dean for clinical research at Weill Cornell Medical College, vice chairman for clinical research in the Department of Medicine, and the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology. He also serves as clinical director of the Weill Cornell Lymphoma Program, attending physician at NewYork-Presbyterian/Weill Cornell Medical Center, and is associate director for Clinical Research of the Weill Cornell Cancer Center.

Dr. Leonard’s two-year term as Chair began July 1, 2012.

Comprised of the world’s leading lymphoma researchers and oncologists, the Scientific Advisory Board formulates the LRF research portfolio, seeking out the most innovative and promising lymphoma research projects for support. The board reviews grant proposals and makes recommendations regarding research priorities and funding to the Foundation Board of Directors. The board also evaluates the progress of on-going research projects and guides the  direction of the Foundation’s research programs.

ASCO Update: Lenalidomide + Rituximab Superior to Lenalidomide Alone in Relapsed Lymphoma

John Leonard, MD

At the recent meeting of the American Society of Clinical Oncology (ASCO), Dr. John Leonard, the director of the Weill Cornell Lymphoma Program, presented the results of the CALGB 50401 trial. The trial compared lenalidomide plus rituximab versus lenalidomide alone in 94 patients with previously treated follicular lymphoma.

Although significant side effects were similar in both treatment arms, the patients treated with the lenalidomide plus rituximab were more likely to respond to treatment (75% vs. 49%) and remain on treatment compared to lenalidomide alone. Based on these results, the investigators concluded that the lenalidomide-rituximab regimen should be considered as a platform for addition of new drugs in future studies.

Click here to read the published abstract.